Cytoreductive nephrectomy is the current treatment paradigm for metastatic renal cell carcinoma (RCC). However, the introduction of targeted therapies has dramatically changed the treatment landscape and may limit the role of nephrectomy in this disease. The recent CARMENA trial supports initial medical treatment of patients with RCC and synchronous metastases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Mejean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1803675 (2018).
Bex, A. et al. Immediate versus deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) [abstract LBA35]. Ann. Oncol. 28 (suppl. 5), v605–v649 (2017).
Heng, D. Y. C. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. 66, 704–710 (2014).
Harshman, L. C. et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 13, 927–935 (2012).
Choueiri, T. K. et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J. Cancer 94, 115–125 (2018).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl J. Med. 378, 1277–1290 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.G. reports grants, personal fees and non-financial support from Bristol-Myers Squibb (BMS), grants, personal fees and non-financial support from Merck Sharp and Dohme (MSD), personal fees and non-financial support from Roche, personal fees and non-financial support from Novartis, grants and personal fees from Pfizer, grants and personal fees from AstraZeneca, personal fees from Eisai, personal fees and non-financial support from Ipsen, personal fees from EUSA Pharma and personal fees from Cerulean. A.B. reports advisory boards from Pfizer, BMS, Ipsen, Roche and Genentech. He is the principle investigator of SURTIME and received a research grant from Pfizer and the European Organisation for Research and Treatment of Cancer (EORTC).
Rights and permissions
About this article
Cite this article
Grünwald, V., Bex, A. The role of nephrectomy in metastatic renal cell carcinoma. Nat Rev Nephrol 14, 601–602 (2018). https://doi.org/10.1038/s41581-018-0041-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-018-0041-3
